ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
123.766,97
-0,44%
S&P 500
5.470,09
-0,23%
US Dollar vs BRL
5,5834
1,48%
Bitcoin
60.244,96
-2,21%
Brent Oil
84,785
-0,74%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Intellia Therapeutics Inc (NTLA)

  7. Intellia Therapeutics Inc (NTLA) Notícias

NTLA

Intellia Therapeutics (NTLA)

Intellia Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:NTLA
DataHoraFonteTítuloCódigoCompanhia
26/06/202408:30GlobeNewswire Inc.Intellia Therapeutics Announces CFO TransitionNASDAQ:NTLAIntellia Therapeutics Inc
25/06/202416:30GlobeNewswire Inc.Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery PlatformNASDAQ:NTLAIntellia Therapeutics Inc
17/06/202408:30GlobeNewswire Inc.Intellia Therapeutics to Present the First-Ever Clinical Data From Patients Redosed with an Investigational In Vivo CRISPR Gene Editing Therapy at the Peripheral Nerve Society Annual Meeting 2024NASDAQ:NTLAIntellia Therapeutics Inc
14/06/202417:24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NTLAIntellia Therapeutics Inc
14/06/202417:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
14/06/202408:30GlobeNewswire Inc.Intellia Therapeutics Names Brian Goff to its Board of DirectorsNASDAQ:NTLAIntellia Therapeutics Inc
02/06/202409:00GlobeNewswire Inc.Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)NASDAQ:NTLAIntellia Therapeutics Inc
09/05/202417:25Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NTLAIntellia Therapeutics Inc
09/05/202408:30GlobeNewswire Inc.Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company ProgressNASDAQ:NTLAIntellia Therapeutics Inc
02/05/202408:30GlobeNewswire Inc.Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company UpdatesNASDAQ:NTLAIntellia Therapeutics Inc
29/04/202408:30GlobeNewswire Inc.Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024NASDAQ:NTLAIntellia Therapeutics Inc
18/03/202408:30GlobeNewswire Inc.Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with CardiomyopathyNASDAQ:NTLAIntellia Therapeutics Inc
26/02/202409:04Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:NTLAIntellia Therapeutics Inc
22/02/202418:11Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NTLAIntellia Therapeutics Inc
22/02/202418:02Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NTLAIntellia Therapeutics Inc
22/02/202409:30GlobeNewswire Inc.Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:NTLAIntellia Therapeutics Inc
15/02/202409:30Business WireIntellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic FibrosisNASDAQ:NTLAIntellia Therapeutics Inc
14/02/202409:30GlobeNewswire Inc.Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company UpdatesNASDAQ:NTLAIntellia Therapeutics Inc
31/01/202419:00GlobeNewswire Inc.Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of MedicineNASDAQ:NTLAIntellia Therapeutics Inc
29/01/202418:00Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NTLAIntellia Therapeutics Inc
08/01/202418:05Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
04/01/202418:01GlobeNewswire Inc.Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key MilestonesNASDAQ:NTLAIntellia Therapeutics Inc
24/11/202311:30Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:NTLAIntellia Therapeutics Inc
14/11/202309:30GlobeNewswire Inc.Intellia Therapeutics Receives European Union Orphan Drug Designation for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary AngioedemaNASDAQ:NTLAIntellia Therapeutics Inc
09/11/202309:30GlobeNewswire Inc.Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:NTLAIntellia Therapeutics Inc
02/11/202308:00GlobeNewswire Inc.Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 at the 4th International ATTR Amyloidosis MeetingNASDAQ:NTLAIntellia Therapeutics Inc
26/10/202308:30GlobeNewswire Inc.Intellia Therapeutics to Present Updated Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis and Hold Conference Call to Discuss Third Quarter 2023 Earnings in NovemberNASDAQ:NTLAIntellia Therapeutics Inc
18/10/202308:00GlobeNewswire Inc.Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with CardiomyopathyNASDAQ:NTLAIntellia Therapeutics Inc
13/10/202309:38GlobeNewswire Inc.Intellia Therapeutics Receives Priority Medicines (PRIME) Designation From the European Medicines Agency for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary AngioedemaNASDAQ:NTLAIntellia Therapeutics Inc
03/10/202308:00GlobeNewswire Inc.Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular DiseasesNASDAQ:NTLAIntellia Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:NTLA

Seu Histórico Recente

BOV
AZEV4
AZEVEDO PN
BOV
IBOV
Índice Bovespa
BOV
HAGA3
HAGA ON
BOV
COGN3
COGNA ON
BOV
GOLL4
GOL PN
BOV
RRRP3
3R Petroleum Oleo E Gas ... ON
BOV
RCSL4
RECRUSUL PN
BOV
PRIO3
PETRORIO ON
BOV
HBOR3
HELBOR ON
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
OIBR4
OI PN
BOV
TECN3
TECHNOS ON
BOV
VVEO3
CM Hospitalar ON
BOV
MGLU3
MAGAZINE LUIZA ON
BOV
AZEV3
AZEVEDO ON
BOV
HOOT4
HOTEIS OTHON PN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados